PITTSBURGH, Oct. 18 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its motion for a preliminary injunction against GlaxoSmithKline and Apotex pertaining to generic Paxil CR was denied at a hearing today in the U.S. District Court for the District of New Jersey. The company believes that the court erred in its decision and intends to appeal.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.